Inhibrx Biosciences, Inc. (INBX) shareholders
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 1,489,443 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Viking Global Opportunities Parent GP LLC Joint filing with Viking Global Investors LP (9.99%), Halvorsen Ole Andreas (9.99%) and 4 more | 1,461,633 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 1,461,105 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Viking Global Investors LP Joint filing with Viking Global Opportunities Parent GP LLC (9.30%), Halvorsen Ole Andreas (9.30%) and 4 more | 1,383,621 | 9.30% | 13G (passive) amendment | Jun 30, 2026 |
| Sanofi | 1,157,926 | 8.00% | 13G (passive) | May 30, 2024 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (6.30%) | 1,155,416 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Jon Faiz Kayyem | 1,149,046 | 7.90% | 13D (active) amendment | Jun 3, 2024 |
| Mark Lappe | 925,413 | 6.40% | 13D (active) amendment | Sep 12, 2024 |
| Schonfeld Strategic Advisors LLC | 781,678 | 5.33% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 768,130 | 5.30% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INBX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 1,308,051 | 8.89% | $123.94M | +44,973 | 0.01% |
| Perceptive Advisors LLC | 1,297,763 | 8.82% | $122.96M | −144,944 | 1.85% |
| Sanofi | 1,157,926 | 7.87% | $109.71M | – | 20.54% |
| Viking Global Investors LP | 1,123,929 | 7.64% | $106.49M | −313,776 | 0.30% |
| HighTower Advisors, LLC | 870,551 | 5.92% | $82.48M | +351 | 0.08% |
| Bank Of America Corp /De/ | 841,141 | 5.72% | $79.70M | +808,458 | 0.01% |
| BlackRock, Inc. | 825,972 | 5.61% | $78.26M | +27,074 | 0.00% |
| Schonfeld Strategic Advisors LLC | 697,586 | 4.74% | $66.10M | +442,759 | 0.24% |
| State Street Corp | 640,458 | 4.35% | $60.68M | +89,613 | 0.00% |
| Vanguard Capital Management LLC | 492,477 | 3.35% | $46.66M | +6,055 | 0.00% |
| Woodline Partners LP | 400,892 | 2.72% | $37.98M | +16,459 | 0.12% |
| Capital Research Global Investors | 363,050 | 2.47% | $34.40M | −29,797 | 0.00% |
| Goldman Sachs Group Inc | 338,176 | 2.30% | $32.04M | +243,102 | 0.00% |
| PFM Health Sciences, LP | 308,385 | 2.10% | $29.22M | +2,954 | 2.51% |
| Sofinnova Investments, Inc. | 303,103 | 2.06% | $28.72M | −102,926 | 1.48% |
| Healthcare Of Ontario Pension Plan Trust Fund | 271,700 | 1.85% | $25.74M | +101,000 | 0.04% |
| Parkman Healthcare Partners LLC | 256,950 | 1.75% | $24.35M | New | 2.49% |
| Geode Capital Management, LLC | 256,175 | 1.74% | $24.28M | +24,666 | 0.00% |
| First Turn Management, LLC | 164,783 | 1.12% | $15.61M | New | 1.67% |
| Millennium Management LLC | 147,200 | 1.00% | $13.95M | −180,660 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 163 | 14M | 97.4% | 52 / 56 | 39 / 21 | 3M | 2M |
| Q1 2026 | 135 | 13M | 86.4% | 25 / 53 | 36 / 27 | 2M | 1M |
| Q4 2025 | 138 | 13M | 87.0% | 45 / 38 | 38 / 8 | 3M | 1M |
| Q3 2025 | 102 | 11M | 71.4% | 25 / 23 | 34 / 11 | 2M | 2M |
| Q2 2025 | 88 | 10M | 70.9% | 10 / 22 | 34 / 14 | 1M | 1M |
| Q1 2025 | 92 | 11M | 73.3% | 9 / 18 | 37 / 16 | 1M | 1M |
| Q4 2024 | 102 | 11M | 76.1% | 17 / 31 | 30 / 10 | 3M | 1M |
| Q3 2024 | 96 | 9M | 60.7% | 22 / 35 | 18 / 11 | 2M | 2M |
| Q2 2024 | 87 | 10M | 66.0% | 87 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
149 funds held INBX in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INBX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,645,973 | 11.18% | $1.07M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 794,436 | 5.40% | $1.33M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 401,027 | 2.72% | $38.00M | 0.35% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 369,641 | 2.51% | $35.02M | 0.00% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 353,292 | 2.40% | $33.47M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 244,118 | 1.66% | $23.13M | 0.03% | Jun 30, 2026 |
| The Merger Fund | 198,509 | 1.35% | $223.32K | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 193,298 | 1.31% | $322.81K | 0.00% | Jun 30, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 164,173 | 1.12% | $0 | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 109,883 | 0.75% | $10.41M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 106,185 | 0.72% | $177.33K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 103,938 | 0.71% | $8.53M | 0.03% | Jul 31, 2026 |
| Meridian Small Cap Growth Fund | 96,915 | 0.66% | $69.78K | 0.03% | Jun 30, 2026 |
| Tax-Managed U.S. Mid & Small Cap Fund | 95,150 | 0.65% | $61.61K | 0.00% | Jul 31, 2026 |
| iShares Biotechnology ETF | 76,625 | 0.52% | $7.26M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark Lappe | Chief Executive Officer, Director | 970,453 | 6.59% | Oct 14, 2026 |
| David Matly | President | – | – | Apr 27, 2026 |
| Kelly Deck | Chief Financial Officer | – | – | Apr 2, 2025 |
| Jon Faiz Kayyem | Director | 1,074,046 | 7.30% | Sep 23, 2026 |
| Douglas Forsyth | Director | 227,064 | 1.54% | Sep 18, 2026 |
| Kristiina Vuori MD | Director | 20,443 | 0.14% | Sep 18, 2026 |
| Kimberly Manhard | Director | 7,500 | 0.05% | Sep 18, 2026 |
| David C. Ott | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities GP LLC Viking | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Illiquid Investments Sub-Master LP Viking | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Portfolio GP LLC Viking | 10% owner | – | – | Oct 9, 2025 |
| Rose Sharon Shabet | 10% owner | – | – | Oct 9, 2025 |
| Global Opportunities Parent GP LLC Viking | 10% owner | 102,864 | 0.70% | Oct 9, 2025 |
| Ole Andreas Halvorsen | 10% owner | 83,333 | 0.57% | Oct 9, 2025 |
| Global Investors Lp Viking | 10% owner | – | – | Oct 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +100 | $85.76 | $8.58K | 170,000 |
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +2,451 | $85.00 | $208.33K | 169,900 |
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +2,449 | $84.07 | $205.89K | 167,449 |
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +100 | $85.76 | $8.58K | 745,588 |
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +2,470 | $85.00 | $209.95K | 745,488 |
| Mark Lappe Chief Executive Officer, Director | Oct 14, 2026 | Buy | +2,470 | $84.07 | $207.65K | 743,018 |
| Mark Lappe Chief Executive Officer, Director | Sep 28, 2026 | Buy | +3,000 | $101.70 | $305.10K | 740,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 28, 2026 | Buy | +1,500 | $98.88 | $148.32K | 737,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 25, 2026 | Buy | +2,176 | $99.60 | $216.73K | 736,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 25, 2026 | Buy | +3,324 | $98.87 | $328.64K | 733,872 |
| Jon Faiz Kayyem Director | Sep 23, 2026 | Buy | +5,000 | $100.00 | $500.00K | 434,360 |
| Jon Faiz Kayyem Director | Sep 16, 2026 | Buy | +5,000 | $100.00 | $500.00K | 429,360 |
| Kimberly Manhard Director | Sep 15, 2026 | Sale | −500 | $105.05 | $52.53K | 7,500 |
| Kimberly Manhard Director | Sep 14, 2026 | Sale | −500 | $110.26 | $55.13K | 8,000 |
| Kimberly Manhard Director | Sep 11, 2026 | Sale | −500 | $111.78 | $55.89K | 8,500 |
| Kimberly Manhard Director | Sep 9, 2026 | Sale | −500 | $115.80 | $57.90K | 9,000 |
| Kimberly Manhard Director | Sep 8, 2026 | Sale | −500 | $115.14 | $57.57K | 9,500 |
| Douglas Forsyth Director | Sep 8, 2026 | Buy | +2,500 | $114.65 | $286.63K | 227,064 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +1,100 | $107.12 | $117.83K | 719,148 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +6,605 | $100.64 | $664.73K | 718,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +5,895 | $99.29 | $585.31K | 711,443 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +1,219 | $111.88 | $136.38K | 720,867 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +9,681 | $112.28 | $1.09M | 730,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 8, 2026 | Buy | +500 | $108.24 | $54.12K | 719,648 |
| Jon Faiz Kayyem Director | Sep 8, 2026 | Buy | +5,000 | $113.52 | $567.60K | 424,360 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −25,042 | $32.25 | $807.60K | 102,864 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −308,643 | $32.25 | $9.95M | 1,267,823 |
| Global Opportunities Parent GP LLC Viking 10% owner | Oct 7, 2025 | Sale | −16,315 | $32.25 | $526.16K | 67,018 |
| Jon Faiz Kayyem Director | Mar 27, 2025 | Gift | −90,000 | – | – | 419,360 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | +250,000 | – | – | 250,000 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | −500,000 | – | – | 509,360 |
| Jon Faiz Kayyem Director | Dec 16, 2024 | Gift | +250,000 | – | – | 250,000 |
| Jon Faiz Kayyem Director | Dec 6, 2024 | Gift | −52,000 | – | – | 1,009,360 |
| Jon Faiz Kayyem Director | Nov 20, 2024 | Buy | +18,750 | $14.19 | $266.06K | 69,843 |
| Jon Faiz Kayyem Director | Nov 20, 2024 | Buy | +18,750 | $14.19 | $266.06K | 69,843 |
| Jon Faiz Kayyem Director | Nov 19, 2024 | Buy | +34,843 | $14.23 | $495.82K | 51,093 |
| Jon Faiz Kayyem Director | Nov 19, 2024 | Buy | +34,843 | $14.23 | $495.82K | 51,093 |
| Kristiina Vuori MD Director | Oct 3, 2024 | Buy | +6,667 | $15.00 | $100.01K | 20,443 |
| Mark Lappe Chief Executive Officer, Director | Sep 16, 2024 | Buy | +13,037 | $17.13 | $223.32K | 705,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 12, 2024 | Buy | +26,963 | $15.05 | $405.79K | 692,511 |
| Kristiina Vuori MD Director | Sep 11, 2024 | Buy | +6,457 | $15.07 | $97.31K | 13,776 |
| Kristiina Vuori MD Director | Sep 10, 2024 | Buy | +179 | $15.00 | $2.69K | 7,319 |
| Mark Lappe Chief Executive Officer, Director | Sep 10, 2024 | Buy | +8,500 | $15.19 | $129.12K | 665,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 9, 2024 | Buy | +9,500 | $15.21 | $144.50K | 657,048 |
| Mark Lappe Chief Executive Officer, Director | Sep 6, 2024 | Buy | +26,000 | $15.29 | $397.54K | 647,548 |
| Mark Lappe Chief Executive Officer, Director | Sep 3, 2024 | Buy | +15,288 | $15.66 | $239.41K | 160,288 |
| Mark Lappe Chief Executive Officer, Director | Sep 3, 2024 | Buy | +4,712 | $16.31 | $76.85K | 165,000 |
| Mark Lappe Chief Executive Officer, Director | Aug 30, 2024 | Buy | +10,000 | $14.02 | $140.20K | 145,000 |
| Kristiina Vuori MD Director | Aug 29, 2024 | Buy | +7,140 | $14.00 | $99.96K | 7,140 |
| Mark Lappe Chief Executive Officer, Director | Aug 29, 2024 | Buy | +10,000 | $14.03 | $140.30K | 135,000 |
| Kimberly Manhard Director | Aug 28, 2024 | Buy | +10,000 | $13.98 | $139.80K | 10,000 |
| Douglas Forsyth Director | Aug 23, 2024 | Buy | +59,812 | $14.07 | $841.55K | 224,564 |
| Douglas Forsyth Director | Aug 22, 2024 | Buy | +15,188 | $12.89 | $195.77K | 164,752 |
| Mark Lappe Chief Executive Officer, Director | Aug 21, 2024 | Buy | +12,945 | $12.93 | $167.38K | 54,865 |
| Mark Lappe Chief Executive Officer, Director | Aug 20, 2024 | Buy | +27,055 | $12.97 | $350.90K | 41,920 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | +10,000 | – | – | 16,250 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | −89,050 | – | – | 1,061,360 |
| Jon Faiz Kayyem Director | Jun 24, 2024 | Gift | +10,000 | – | – | 16,250 |
| Jon Faiz Kayyem Director | Jun 5, 2024 | Buy | +49,284 | $17.23 | $849.16K | 1,142,145 |
| Jon Faiz Kayyem Director | Jun 5, 2024 | Buy | +8,265 | $17.89 | $147.86K | 1,150,410 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inhibrx Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,034 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kimberly Manhard Director | Sep 15, 2026 | 500 | $52.53K | Sep 15, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 14, 2026 | 500 | $55.13K | Sep 14, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 11, 2026 | 500 | $55.89K | Sep 11, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 9, 2026 | 500 | $57.90K | Sep 9, 2026 | Open Market Purchase |
| Kimberly Manhard Director | Sep 8, 2026 | 500 | $57.57K | Sep 8, 2026 | Open Market Purchase |
See a number that looks wrong?